2. Signaling Pathways
  3. Immunology/Inflammation
  4. Transmembrane Glycoprotein
  5. Transmembrane Glycoprotein Inhibitor

Transmembrane Glycoprotein Inhibitor

Transmembrane Glycoprotein Inhibitors (68):

Cat. No. Product Name Effect Purity
  • HY-P99054
    Tusamitamab
    		Inhibitor 99.75%
    Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative).
  • HY-157122
    VJDT
    		Inhibitor 99.68%
    VJDT is a TREM1 small molecule inhibitor that effectively blocks TREM1 signaling. VJDT inhibits tumor growth and can be used in cancer research.
  • HY-P99208
    Lirilumab
    		Inhibitor
    Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
  • HY-149898
    HA-CD44 interaction inhibitor 1
    		Inhibitor 98.93%
    Antitumor agent-109 (compound 6) is an inhibitor of hyaluronic acid (HY-B0633A) targeting to CD44, as well as an anti-tumor agent. Hyaluronic acid interacts with differentiation cluster 44 (CD44) and is involved in tumor growth and invasion. Antitumor agent-109 inhibits MDA-MB-231 cells with EC50 value of 0.59 μM.
  • HY-P99160
    Labetuzumab
    		Inhibitor 99.59%
    Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy.
  • HY-149897
    HA-CD44 interaction inhibitor 2
    		Inhibitor 99.04%
    HA-CD44 interaction inhibitor 2 (compound 5) is an Hyaluronic acid (HA)-CD44 interaction inhibitor that effectively disrupts the integrity of cancer spheroids. HA-CD44 interaction inhibitor 2 also exhibits antiproliferative activity against cancer cells.
  • HY-P99237
    Sofituzumab
    		Inhibitor
    Sofituzumab (MMUC 1206A) is a humanizedized anti-MUC16 recombinant V-kappa antibody.
  • HY-P99129
    Anti-Mouse CD8a Antibody (53-6.7)
    		Inhibitor
    Anti-Mouse CD8a Antibody is a anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat.
  • HY-P99202
    Vibostolimab
    		Inhibitor
    Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.
  • HY-P990673
    Vandortuzumab
    		Inhibitor 99.00%
    Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-144399
    CD33 splicing modulator 1
    		Inhibitor 99.55%
    CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease.
  • HY-P9983
    Lintuzumab
    		Inhibitor 98.09%
    Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.
  • HY-P990294
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)
    		Inhibitor
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD106/VCAM-1.
  • HY-P990032
    Belrestotug
    		Inhibitor
    Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity.
  • HY-P99958
    Vixtimotamab
    		Inhibitor
    Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).
  • HY-137605
    WSF1-IN-1
    		Inhibitor 99.91%
    WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC50 values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively.
  • HY-P990259
    Anti-Mouse CD96 Antibody (3.3)
    		Inhibitor
    Anti-Mouse CD96 Antibody (3.3) is a rat-derived IgG1, λ type antibody inhibitor, targeting to mouse CD96.
  • HY-113481
    Prostaglandin E3
    		Inhibitor ≥99.0%
    Prostaglandin E3 is an eicosanoid derived from eicosapentaenoic acid. Prostaglandin E3 inhibits polarization towards M1 but promotes polarization of M2a macrophages. Prostaglandin E3 shows anti-inflammatory and anti-tumor activity.
  • HY-110104
    8MDP
    		Inhibitor
    8MDP is a potent equilibrative nucleoside transporter 1 (ENT1) inhibitor with an IC50 of 0.43 nM. 8MDP inhibits hENT1 and hENT2 uptake of [H3] uridine by K562 cells and K15NTD cells.
  • HY-P990351
    Anti-CD34 Antibody
    		Inhibitor
    The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).